Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lilly-Novast Partnership to Build China Manufacturing Facility

publication date: Mar 5, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
The Eli Lilly-Novast Laboratories partnership began expanding a manufacturing facility in Nantong, China that will produce a line of Lilly branded generics for the China market. The two companies formed a strategic partnership in 2012 when Lilly invested $20 million in Novast, its second investment in the company. The expansion, which will cost $60-$70 million, will add 260,000 square feet of manufacturing space. It will produce 2.2 billion units of sustained release and solid oral dosage pharmaceuticals annually. More details...

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...